Initial Public Offering

SkyeChip's IPO demand signals Asia wants its own NVIDIA proxies. The Penang-based chip designer drew 95x oversubscription for its public tranche, the largest retail demand since Petronas Chemicals in 2010. Malaysia's 2026 IPO proceeds are tracking toward $1.8 billion, the highest in 13 years, driven by tech listings and REIT spin-offs. Khazanah, EPF and other sovereign funds anchored the deal, betting on Malaysia's push to move beyond back-end semiconductor assembly into higher-value AI chip design. The frenzy mirrors Samsung's $1 trillion valuation spike as regional markets chase AI infrastructure plays.

The private equity giant is capitalizing on AI infrastructure demand through public markets.

The largest energy IPO ever just validated geothermal as AI infrastructure. Fervo priced at $27 per share, raising $1.89 billion in an oversubscribed offering that values the company at $7.7 billion. The Houston startup applies fracking techniques to hot rock formations, creating enhanced geothermal systems that generate 24/7 clean power exactly when AI data centers need it most. Hyperscalers like Google and Microsoft are desperate for baseload renewables as AI workloads surge, making Fervo's 3GW pipeline suddenly precious. The company's Cape Station project targets $70 per kilowatt initially, dropping to under $30/kW as production scales. With 42GW of additional potential capacity, Fervo is betting AI's insatiable appetite for always-on clean energy justifies premium valuations in a sector notorious for broken promises.

The wafer-scale processor maker is reportedly considering raising its IPO price to $150-160 per share, up from an initial $115-125 range, as institutional demand builds for alternatives to Nvidia's dominance. Strong investor appetite has already pushed the company to revise targets twice in a week, potentially valuing the business above $30 billion compared to February's $23 billion private round. OpenAI appears as the dominant customer in SEC filings, creating concentration risk but also validating commercial traction. If Cerebras prices at the high end, it would mark the largest US tech IPO of 2026 and test whether public markets will pay premium valuations for specialized AI silicon.

The antidepressant maker priced its IPO at the top of the range, targeting a $912 million valuation for technology that promises oral bioavailability without the liver damage typical of neuropsychiatric drugs. Seaport's lead candidate SPT-300 advances into Phase 2b studies for major depression, with Goldman Sachs and JPMorgan underwriting the deal despite the company being barely two years old. The Glyph platform's ability to bypass first-pass metabolism could be genuinely disruptive, or it could be another biotech betting that novel delivery mechanisms will overcome the industry's 90% failure rate. Investors clearly believe the former, but Phase 2b data will settle the question.

Avalyn Pharma priced its IPO at the top of range and upsized to $300 million, making it one of 2026's largest biotech debuts. The inhaled lung disease specialist targets 100,000 US patients with reformulated versions of approved drugs Esbriet and Ofev, avoiding the oral side effects that plague current treatments. Novo Holdings backs the Boston company with 13% ownership, betting $150 million of IPO proceeds on Phase 3 trials. The biotech IPO median has soared past $287 million in 2026, double last year's figure, as investors warm to derisked drug development over moonshot research.

Masayoshi Son wants to create and list a new AI company called Roze in the US this year, targeting a $100 billion valuation focused on data centers. The move comes after SoftBank invested $30 billion in OpenAI at a $260 billion pre-money valuation, selling nearly $6 billion of Nvidia stock to fund the deal. SoftBank also committed $4 billion to DigitalBridge and leads the Stargate data center project with OpenAI and Oracle. Son is aggressively expanding AI infrastructure bets as his portfolio company faces potential trillion-dollar valuations. The Roze listing would tap deeper US capital markets while monetizing SoftBank's 300-plus AI and robotics investments.

India's used-car market is about to test public investors' appetite for inventory-heavy business models. Spinny has engaged investment banks for a Mumbai listing, joining peers CARS24 and CarDekho in pursuing IPOs that could collectively raise over $1 billion within 18 months. The company raised $131 million in pre-IPO funding at a flat $1.7 billion valuation while cutting losses by 28 percent to INR 424 crore for the second consecutive year as financial reports detail. Spinny's acquisition of automotive media titles signals a bet that content can drive trust in an industry where procurement costs and refurbishment expenses still plague unit economics. Early backers like Tiger Global need exits, and India's hot IPO market offers the best window in years.

Nuclear startups are suddenly bankable as hyperscale data centers devour electricity faster than grids can supply it. X-Energy raised $1.02bn in its public debut with Amazon leading the charge, betting small modular reactors can solve AI's power bottleneck within the decade. The IPO values X-Energy at $3.2bn despite zero commercial reactors operating, a premium that reflects Silicon Valley's desperation for carbon-free baseload power. Amazon needs 40GW of new capacity by 2030 for its data center expansion, equivalent to powering 30 million homes. Traditional renewables cannot match nuclear's density and reliability, making these reactors the only viable path to AI scale without carbon guilt.

Zelos, backed by Alibaba, plans a $600 million Hong Kong IPO as Chinese tech companies return to public markets after two years of regulatory crackdowns. The timing tests whether international investors will re-embrace Chinese growth stories or remain skeptical of regulatory risks. Success could open the floodgates for other Alibaba portfolio companies seeking liquidity. The IPO also serves as a barometer for Hong Kong's ability to compete with US exchanges for high-growth tech listings.

Arxis Technology priced its IPO at the top of its range, pulling $1.13 billion from investors betting on a sustained defence spending boom. The aerospace parts manufacturer's revenue jumped 47 percent last year as Western nations rebuilt weapon stockpiles depleted by Ukraine aid. Separately, Accel closed a $5 billion late-stage fund, its largest ever, signaling venture capital's flight to quality continues. Both deals suggest institutional money is concentrating in sectors with government backing or proven cash generation.

The wellness IPO pipeline just got another player. Suja Life, the cold-pressed juice company, filed for a public offering after posting 26% sales growth, with sources pegging its valuation near $1 billion. The company's running a dual-track process — IPO or sale — giving it flexibility if public markets turn sour. Cambridge SPG, the private equity owner, is clearly testing appetite for premium organic beverages amid economic uncertainty. It's another bet that health-conscious consumers will pay up even when budgets tighten — a thesis that's worked for some but crushed others in this market.

Malaysian tycoon Syed Mokhtar Albukhary's MMC Ports has secured regulatory approval for a Main Market IPO that could raise $2 billion at a $7 billion valuation, potentially Malaysia's largest since FGV Holdings in 2012. The company operates Southeast Asia's largest private port network by equity-adjusted throughput, handling 18.5 million TEUs and serving four of Malaysia's five largest container ports. The November debut comes as supply chain reshoring to Southeast Asia drives logistics sector consolidation.